FDA approved Immgolis Intri (golimumab-sldi) as an interchangeable biosimilar to Simponi Aria (golimumab).
What this means
Immgolis Intri is a biosimilar version of Simponi Aria, a drug that blocks TNF-alpha, a protein involved in inflammation. Today FDA approved Immgolis Intri as interchangeable with Simponi Aria, meaning pharmacists can substitute it without consulting the prescribing doctor. This approval could increase access to treatment for inflammatory conditions like rheumatoid arthritis by offering a lower-cost alternative.
